<DOC>
	<DOC>NCT00650637</DOC>
	<brief_summary>The purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.</brief_summary>
	<brief_title>A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Antiretroviralnaive patients with HIV1 infection not more than 2 loose stools per day or any preexisting or emerging medical condition that would interfere with the evaluation of therapeutic response of the study drug No antidiarrheal medication within 7 days prior to entry Greater than or equal to 2 loose stools per day lasting 2 or more days within 7 days prior to study entry Bloody stools within 7 days prior to study entry Any unstable or severe intercurrent medical condition, including active opportunistic infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>